Intimation of Resignation of Managing Director under regulation 30 of SEBI(LODR) Regulation 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mr. Altaf Hussain (DIN: 10351528) has resigned from the dual role of Managing Director and Chief Financial Officer of Welcure Drugs & Pharmaceuticals Ltd, effective from close of business hours on 5th May 2025. He cited personal reasons and other professional commitments for his departure, and confirmed there are no other material reasons behind his exit. The Board of Directors has acknowledged his resignation and recorded appreciation for his contributions during his tenure. The resignation was communicated to BSE on 6th May 2025 under Regulation 30 of SEBI (LODR) Regulations, and the company has stated he holds no other directorships in listed entities.
The sudden exit of the person handling both the MD and CFO roles could create short-term leadership and financial oversight uncertainty. Shareholders should watch for timely disclosures regarding interim arrangements and the appointment of a new MD and/or CFO, as prolonged vacancies at this level may affect investor confidence and stock sentiment.